BioStar Capital is a value-add investment firm focused on transformational medical device technologies in cardiovascular and orthopaedic medicine. Combining the insight of experienced investment professionals and world-renowned medical thought leaders, BioStar Capital identifies proprietary technologies that serve unmet patient needs and fit the acquisition criteria of leading medical device companies. BioStar Capital fills an important gap in medical device innovation and provides operational skills and clinical expertise in addition to capital, enabling the firm to actively mitigate risk, optimize product development, and secure successful exit. The firm has invested in over 30 med-tech companies, many of which have been acquired by a major medical device manufacturer.

BioStar News
Portfolio News

May 25, 2021

Jeffrey Yau, PhD, VP of Data Science and Engineering at Walmart Global Technology, Joins BioStar Capital as Entrepreneur in Residence

>> Read More

January 15, 2021

DeviceTalks Weekly features Mark Toland, BioStar Entrepreneur-in-Residence: Digging into the Digital Medtech & Surgical Worlds

>> Read More

June 10, 2021

TransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting

>> Read More

June 8, 2021

TransMedics Announces Presentation of OCS Liver PROTECT Trial Results and is Recognized as Winner of The People's Choice Award for Most Impactful Presentation at the American Transplant Congress (ATC 2021)

>> Read More

Active Portfolio Companies
ASI Logo - New.png
AVS Logo.png
Foldax Logo (Black).jpg
OO Logo_edited.png
SENS Logo.png
Trice Logo - New.png